Results 61 to 70 of about 297 (139)
Cervical cancer patients with varying responses to neoadjuvant chemotherapy (NACT) exhibit unique patterns of variation in cell‐free DNA (cfDNA) levels and fragmentomic characteristics. The cfDNA emerges as a promising biomarker for predicting tumor response to NACT in cervical cancer, offering a novel approach for monitoring treatment response to ...
Ting Peng +16 more
wiley +1 more source
The origin of ctDNA in the bloodstream is derived from CTC, exosomes secreted by tumor cells, apoptotic tumor cells and necrotic tumor cells (A). ctDNA methylation status plays an important role in the occurrence and development of cancer and is a biomarker for tumor liquid biopsy.
Lingyu Li, Yingli Sun
wiley +1 more source
Circulating Cell-free DNA Fragmentomics Detection and Beyond
Circulating cell-free DNA (cfDNA) comprises DNA fragments released into bodily fluids via apoptosis, necrosis, or phagocytosis. cfDNA encapsulates both fragmentomics (structural) and non-fragmentomics (sequence/epigenetic) information from source cells, thereby representing a promising biomarker.
Tianliang, Liu +3 more
openaire +2 more sources
Advances in early detection of non‐small cell lung cancer: A comprehensive review
Abstract Background Lung cancer has the highest mortality rate among malignancies globally. In addition, due to the growing number of smokers there is considerable concern over its growth. Early detection is an essential step towards reducing complications in this regard and helps to ensure the most effective treatment, reduce health care costs, and ...
Nour Kenaan +6 more
wiley +1 more source
Pregnancy complications contribute substantially to maternal and fetal morbidity and mortality. If complications are suspected early in pregnancy, individuals could be triaged to escalate care and ideally reduce adverse outcomes.
Bernard Thienpont +12 more
core +1 more source
Cell-free DNA fragmentomics for preeclampsia risk assessment
Abstract Preeclampsia (PE) is a pregnancy-specific hypertensive disorder that could lead to serious maternal and fetal complications, yet early identification of women at risk remains challenging because reliable biomarkers are limited.
Wenqiu Xu +39 more
openaire +1 more source
Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]
Rossa W K Chiu +4 more
openaire +1 more source
Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer +26 more
openaire +3 more sources
Mechanistic Modeling of cfDNA Fragmentome Dynamics Predicts Progression to Immunotherapy
BackgroundPlasma cell-free DNA (cfDNA) shows promise as predictive cancer biomarker, but mechanisms governing cfDNA production/fragmentation/elimination dynamics, and their relationships with tumor burden and disease progression, remain poorly understood.
Boutonnet, Audrey +9 more
core +3 more sources
Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer
Background Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately ...
Shan, Lina +11 more
openaire +2 more sources

